Hoechst

Revolutionary Elephant iPSC Milestone Reached in Colossal’s Woolly Mammoth Project

Retrieved on: 
星期三, 三月 6, 2024
Biotechnology, Technology, Health, Environmental Issues, Environmental Health, Other Science, Research, Software, Genetics, Environment, Science, Hoechst, KLF4, CRISPR, Woolly mammoth, Multimedia, Cattle, Growth, Harvard University, Cell, Developmental biology, TP53, Gametogenesis, Colossal Biosciences, Factorization of polynomials, Life, Elephant, IPSC, MYC, Cat, Genome, Gene, OCT4, Rhinoceros, Publication, PCR, Biology, Cancer, Hunting

Colossal Biosciences (“Colossal”), the world’s first de-extinction company, announces today that their Woolly Mammoth team has achieved a global-first iPSC (induced pluripotent stem cells) breakthrough.

Key Points: 
  • Colossal Biosciences (“Colossal”), the world’s first de-extinction company, announces today that their Woolly Mammoth team has achieved a global-first iPSC (induced pluripotent stem cells) breakthrough.
  • This milestone advancement was one of the primary early goals of the mammoth project, and supports the feasibility of future multiplex ex utero mammoth gestation.
  • Invaluable for Colossal’s Woolly Mammoths, these cells can be multiplex-edited and differentiated to study cold adaptation traits like woolly hair growth and fat storage in cellular and organoid models.
  • “In the past, a multitude of attempts to generate elephant iPSCs have not been fruitful.

Press Release: François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee

Retrieved on: 
星期四, 二月 1, 2024
Tax, Growth, Hoechst, Life, CFO, Roussel, Treasury, Education, Management

François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee

Key Points: 
  • François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee
    Paris, February 1, 2024.
  • François-Xavier Roger will be appointed Chief Financial Officer and a member of Sanofi’s Executive Committee effective April 1, 2024.
  • He is a seasoned executive who has lived and worked in Europe, the U.S, Asia, Africa and Latin America.
  • My decision to head Apprentis d’Auteuil was also fuelled by my growing passion for the impact Sanofi has around the world.

EQS-News: Vulcan Energy Resources Limited: Positive local development and permitting progress towards delivery of Phase One of Vulcan’s Zero Carbon Lithium™ Project

Retrieved on: 
星期四, 七月 13, 2023
Lithium, Carbon, Hoechst, Communication, State, Lord, Life, VUL, FSE, CDO, CLP, City, Phase 1, Water, LEP, Commercial property

The G-LEP construction is planned as part of Phase One of Vulcan’s Zero Carbon Lithium™ Project in the Upper Rhine Valley Brine Field.

Key Points: 
  • The G-LEP construction is planned as part of Phase One of Vulcan’s Zero Carbon Lithium™ Project in the Upper Rhine Valley Brine Field.
  • Vulcan plans to extract carbon neutral lithium and supply carbon neutral, renewable heat to the city, as part of its Phase One development.
  • We have worked closely with local stakeholders to progress our Zero Carbon Lithium™ Project plans.
  • Our hard work is paying off, with positive decisions for the Project provided by the Landau City Council and the surrounding planned Phase One project locations.

5E Advanced Materials Appoints Experienced Global Executive as CEO

Retrieved on: 
星期二, 三月 21, 2023
Hoechst, IPO, Ambassador, University, Advanced Materials, Senior, Long Beach, California, California State University, Long Beach, Nissan USA, Engineering, Stanford University, Empowerment, Boron, Dean, Senior plc, ASX, Ford Motor Company, Lithium, Manufacturing, Government, Sale, Critical infrastructure, NYSE, Primary energy, Business administration, Dean Smith (engineer), Doe, Celanese, Nikola Corporation, Transport, Master of Business Administration, University of Nebraska–Lincoln, Education, Complex, Management, Science

HOUSTON, March 21, 2023 (GLOBE NEWSWIRE) -- 5E Advanced Materials, Inc. (Nasdaq: FEAM) (ASX: 5EA) (“5E” or the “Company”), a boron and lithium company with U.S. government Critical Infrastructure designation for its 5E Boron Americas (Fort Cady) Complex, is pleased to advise that it has appointed Ms. Susan Seilheimer Brennan as the Company’s new Chief Executive Officer commencing April 24, 2023.

Key Points: 
  • Prior to her appointment at 5E Advanced Materials, Ms. Brennan was President and CEO of NYSE-listed Romeo Power (NYSE:RMO), a leader in advanced electrification solutions for commercial vehicles
    HOUSTON, March 21, 2023 (GLOBE NEWSWIRE) -- 5E Advanced Materials, Inc. (Nasdaq: FEAM) (ASX: 5EA) (“5E” or the “Company”), a boron and lithium company with U.S. government Critical Infrastructure designation for its 5E Boron Americas (Fort Cady) Complex, is pleased to advise that it has appointed Ms. Susan Seilheimer Brennan as the Company’s new Chief Executive Officer commencing April 24, 2023.
  • Ms. Brennan has an extensive global leadership background, particularly in the battery technology and electric vehicle industries.
  • Most recently, as the CEO of NYSE listed Romeo Power (NYSE: RMO), she was responsible for leading an organization which developed a suite of battery technology products designed for commercial vehicles.
  • As CEO, Ms. Brennan will lead all facets of the Company as it progresses its business strategy to become a fully integrated globally significant producer of boron, lithium and advanced materials based in the United States of America.

EQS-News: VisionHealth raises 3 million Euro to finance extended COPD and asthma study for market preparation of Kata®, an innovative digital therapeutic for improved inhalation

Retrieved on: 
星期一, 二月 27, 2023
Clinical trial, Chronic Respiratory Disease, Single-frequency network, Contract research organization, Life, Respiratory failure, DuPont, Business, MDR, Patient, Chronic obstructive pulmonary disease, Estonia, Hoechst, Growth, Medical device, Therapy, Medical Devices Directive, In Practice Systems Limited, Inhalation, Business development, Asthma, Chronic lung disease, Friends, Hospital, MDD, CE, Physician, Lung, Security (finance), Pharmaceutical industry, COPD, EU

He will take a seat on the non-executive Board of VisionHealth.

Key Points: 
  • He will take a seat on the non-executive Board of VisionHealth.
  • The study is designed as a randomly controlled, multi-centric trial over the period of one year with around 120 patients suffering from chronic respiratory diseases such as asthma or COPD.
  • It is truly rewarding to see how we can make a difference for patients and improve health outcomes.
  • Worldwide, Kata® could support the therapy of approximately 250 million patients suffering from chronic respiratory diseases, with an estimated 8.9 million cases alone in Germany.8,9

Alavi Anaipakos Adds Experienced Intellectual Property Trial Lawyers in Houston

Retrieved on: 
星期三, 二月 22, 2023
Telecommunications, University, Wall, Constitutional law, Computer graphics, Software, Lawyer, Hoechst, United States International Trade Commission, ExxonMobil, Patent, Intellectual property, General Electric, Counsel

HOUSTON, Feb. 22, 2023 /PRNewswire/ -- The trial lawyers at Houston-based Alavi Anaipakos are welcoming two proven attorneys who have joined the firm with extensive track records in high-stakes business lawsuits and intellectual property trials.

Key Points: 
  • Mr. Wall has worked alongside Alavi Anaipakos' attorneys in significant lawsuits on behalf of franchise owners, oil and gas shareholders, and prominent families, among others.
  • "We knew when we launched our firm less than a year ago that we wanted true trial lawyers, which perfectly describes these two excellent attorneys."
  • Mr. Pinckney's trial expertise includes cases involving a broad spectrum of intellectual property disputes covering telecommunications and wireless technologies, system networking, payment systems, computer graphics, home appliances, and many others.
  • Houston-based Alavi Anaipakos is home to high-stakes trial lawyers known for solving complex problems.

Fujifilm’s Life Sciences Corporate Venture Capital Fund Invests in PhenoVista Biosciences

Retrieved on: 
星期二, 十二月 13, 2022
Stem Cells, Biotechnology, Technology, Manufacturing, Professional Services, Health, Pharmaceutical, Photography, Audio, Video, Engineering, Mobile, Wireless, Neuron, HCS, 2D, IPS, Corporate venture capital, Doctor of Philosophy, Partnership, ICELL Network, Patient, Biomedical engineering, Hoechst, Potency (pharmacology), HIV disease progression rates, 3D, Neuroscience, Cell, Ready 2 Go, Multimedia, Growth, Yokogawa Electric, Fine chemical, 3D printing, Medical imaging, Fujifilm

FUJIFILM Corporations Life Sciences Corporate Venture Capital (LS-CVC) strategic investment fund is investing in PhenoVista to accelerate the development of new high-content screening (HCS) assay services using FUJIFILM iCell differentiated induced pluripotent stem cells (iPSCs) and PhenoVistas cutting-edge imaging technologies.

Key Points: 
  • FUJIFILM Corporations Life Sciences Corporate Venture Capital (LS-CVC) strategic investment fund is investing in PhenoVista to accelerate the development of new high-content screening (HCS) assay services using FUJIFILM iCell differentiated induced pluripotent stem cells (iPSCs) and PhenoVistas cutting-edge imaging technologies.
  • Fujifilms investment will accelerate an exciting phase of growth for PhenoVista, further solidifying our position as the leader in imaging-based analysis of complex cell models, said James G. Evans, CEO and co-founder of PhenoVista Biosciences.
  • Launched in February 2022, LS-CVC is a newly established group within Fujifilms Life Sciences Strategy Headquarters in Tokyo.
  • PhenoVista Biosciences is a leading provider of disease-relevant cell-based assay services based in San Diego, California.

EQS-News: HepaRegeniX appoints Dr. Andreas Busch as Senior Advisor

Retrieved on: 
星期日, 十一月 27, 2022
Doctor of Philosophy, German Cancer Aid, MKK4, 2021 Essex County Council election, University, Therapy, Bayer, Sanofi, Patient, Senior advisor, Liver regeneration, Max Planck Institute for Molecular Genetics, Max, German Cancer Research Center, Transplant, Innovation, Max Planck Society, Pharmacy, Shire, Research, Publication, Hoechst, Survival, Takeda, Drug discovery, Pharmaceutical industry, Pharmacology

Tbingen (Germany), November 23, 2022 HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapy approaches for the treatment of acute and chronic liver diseases, announced today the appointment of Dr. Andreas Busch as Senior Advisor.

Key Points: 
  • Tbingen (Germany), November 23, 2022 HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapy approaches for the treatment of acute and chronic liver diseases, announced today the appointment of Dr. Andreas Busch as Senior Advisor.
  • We are thrilled to welcome Andreas Busch to our team.
  • Dr. Andreas Busch added: There is an enormous lack of organs for transplantation including of livers despite their unique inherent regenerative capabilities.
  • Dr. Andreas Busch has an extensive track record in facilitating innovation both in the pharmaceutical industry as well as in academic research.

Absci Appoints Veteran Pharma Executive Andreas Busch, PhD as Chief Innovation Officer

Retrieved on: 
星期二, 十月 4, 2022
YouTube, CNS, Max Planck Society, Translation, Innovation Center station, U.S. Securities and Exchange Commission, Review, Nasdaq, Drug Quality and Security Act, Therapy, Acquisition, Hoechst, Social media, German Cancer Research Center, Research, Takeda, CEO, Sanofi, Drug design, Development, Leadership, Patient, University, German Cancer Aid, Doctor of Philosophy, Research and development, SEC, Drug discovery, Twitter, Protein, FDA, File, Deep learning, Max Planck Institute for Molecular Genetics, Pharmacy, Publication, Max, GLOBE, Organic acid, Securities Exchange Act of 1934, Drug development, LinkedIn, Technology, 2021 Essex County Council election, Library, Synthetic biology, Concept, NEW, Securities Act of 1933, Medical device, Fine chemical, Pharmaceutical industry, Pharmacology, Bayer

VANCOUVER, Wash. and NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), leaders in the protein drug creation revolution harnessing generative AI and scalable biological data to design better therapeutics, faster, today announced the appointment of Andreas Busch, PhD, as Chief Innovation Officer, where he will be responsible for leading R&D, technical operations, and driving both Absci’s internal and partner programs. As a former pharma R&D executive, Dr. Busch brings substantial R&D expertise to Absci’s leadership team as a world-renowned leader in drug development that has led discovery efforts for some of the globe’s top pharma companies including Sanofi, Bayer, and Shire. His leadership has resulted in over 10 commercial drugs starting from bench to FDA approval with several more in late stage clinical development.

Key Points: 
  • Absci has addressed this data problem through its breakthrough wet lab technology that can interrogate millions-to-billions of protein-protein interactions in a given week.
  • Prior to joining Absci, Dr. Busch served as Chief Scientific Officer and Chief Innovation Officer, Head of the Innovation Center at Cyclerion Therapeutics, Inc., an innovator in CNS biotherapeutics.
  • Before Cyclerion, Dr. Busch served as Executive Vice President, Head of Research & Development and Chief Scientific Officer at Shire prior to their acquisition by Takeda.
  • For more information visit www.absci.com and follow us on social media: Twitter: @Abscibio , LinkedIn: @absci , and subscribe to our Absci YouTube channel .

Directorate Change

Retrieved on: 
星期三, 八月 24, 2022
National Transportation Safety Committee, Committee on Finance, DB, Deutsche Telekom, Dubai Airports Company, Board, Â, AGM, Committee, Supervisory board, Senior, Audit committee, EBay, Advisory board, Kuehne + Nagel, KLM, Lufthansa, Sabre Corporation, DB Schenker, Transport, Hoechst, Travel, Airline, Management, Property management, EasyJet

Harald brings significant experience of the travel and aviation industry, having held senior executive positions with Lufthansa and Sabre Travel Network.

Key Points: 
  • Harald brings significant experience of the travel and aviation industry, having held senior executive positions with Lufthansa and Sabre Travel Network.
  • In addition to Infare, he currently serves as a member of the Advisory Board for Solytic, a German cleantech start-up.
  • Membership of the Committees will change as follows with effect from 1 September 2022:
    Harald Eisencher will become a member of the Remuneration Committee and Finance Committee.
  • I am also pleased that we will continue to benefit from Julie and Andreas experience through to February next year.